Data on sprytne.com is aggregated from official U.S. Government sources including the SEC EDGAR database, USAspending.gov, USPTO, and U.S. Census Bureau. In accordance with 17 U.S.C. § 105, works of the U.S. Government are not subject to copyright protection and reside in the Public Domain. sprytne.com provides value-added visualization and algorithmic analysis of these public records.
Not financial advice. sprytne.com is an automated market intelligence platform. We are not a registered investment advisor, broker, or dealer. Financial metrics, risk scores, and federal award data are for informational purposes only. Past performance (including government contract history) is not indicative of future market results. Verify all data via official SEC.gov filings.
This platform adheres to CCPA/GDPR standards regarding professional and public business data. Information displayed pertains to commercial entities and public officers in their professional capacity. For data verification or removal requests regarding non-public information, please visit our Contact page. Operated under Brand House Data Systems framework.
© 2026 sprytne.com — Institutional Data Intelligence — Federal Transparency Initiative
Ticker BIIB · Nasdaq · DE
BIOGEN INC. is a U.S. business entity operating within the Biological Products, (No Diagnostic Substances) sector (SIC 2836). Publicly traded on the Nasdaq under the ticker symbol BIIB, the company is incorporated in Delaware. Based on SEC EDGAR filings, BIIB reported fiscal year 2025 revenue of $9.89B, reflecting a year-over-year growth of 2.2%. Our proprietary Semantic Risk Score of 14 indicates high transparency and low reporting risk, derived from the frequency and consistency of 10-K, 10-Q, and 8-K filing patterns. As part of the SIC 2836 classification, BIOGEN INC. serves as a key benchmark for investors and analysts monitoring Delaware corporate performance.
Comparison based on Standard Industrial Classification (SIC) mapping from SEC EDGAR filings.
Filing data sourced from SEC EDGAR signals. 10-K = annual report · 10-Q = quarterly · 8-K = material event.
BIOGEN INC. (BIIB) — Key efficiency & solvency metrics · FY2025
Net Margin
Sector avg: -81.49%
Current Ratio
Sector avg: 6.8
| Key Metric | Company | Industry Avg | Status |
|---|---|---|---|
| Total RevenueYoY: +2.2% | $9.89B | $931.8M | ▲ Outperform |
| Net IncomeYoY: -20.8% | $1.29B | — | — |
| Net MarginNet income as % of revenue | 13.1% | -81.49% | ▲ Outperform |
| Current RatioCurrent assets / current liabilities. Above 1.0 = solvent. | 2.68 | 6.8 | ▼ Lagging |
Source: SEC EDGAR XBRL filings (10-K annual reports). Industry benchmarks derived from 101 companies in SIC 2836.
Disclaimer: All financial data is sourced from raw SEC EDGAR filings. Sprytne.com provides automated data visualization and algorithmic analysis for informational purposes only. This is NOT financial advice, a recommendation to buy/sell, or a guarantee of accuracy. Always verify data via official SEC sources before making investment decisions.
Federal Contracts
PURCHASE OF FMD VAC FROM BIOGENESIS BAGO S.A. ORDER SPECIFICS SUCH AS ANTIGENS AND QUANTITY ORDERED ARE FOR OFFICIAL USE ONLY (FOUO)
UTILIZING THE CONTRACTORS TECHNOLOGY, HUMAN INDUCED PLURIPOTENT STEM CELLS WILL UNDERGO DIFFERENTIATION TO PRE-MEGAKARYOCYTES (PREMK+), WHICH ARE STOCKPILED THROUGH CRYOPRESERVATION. FROZEN PREMK+ ARE THAWED AND FURTHER DIFFERENTIATED TO MATURE MEGAK
FY23 FMD VAC FOR NAVVCB FROM BIOGENESIS BAGO
FY21 NAVVCB FMD VAC ORDER FROM BIOGENESIS BAGO S.A.
BG - NAVVCB PURCHASE BIOGENESIS NAVVCB FMD VAC AND RELATED ITEMS
IGF::OT::IGF PROTOTYPE MONITORING, REPORTING AND VERIFICATION SYSTEM FOR THE REGIONAL SCALE: THE BOSTON-DC CORRIDOR. THE WORLD S POPULATION GROWTH IS INCREASINGLY CONCENTRATED IN URBAN AREAS AND THIS TREND IS EXPECTED TO CONTINUE IN THE FUTURE. URBANIZATION HAS A PROFOUND IMPACT ON CARBON DYNAMICS, LEADING TO INCREASES IN ANTHROPOGENIC CARBON DIOXIDE (CO2) EMISSIONS AND DECREASES IN BIOGENIC FLUXES FROM THESE AREAS. THE LATTER ARE A KEY COMPONENT OF A CARBON MONITORING SYSTEM (CMS), WHILE SPATIALLY AND TEMPORALLY RESOLVED ESTIMATES OF ANTHROPOGENIC FLUXES ARE CENTRAL TO MEETING GREENHOUSE GAS EMISSIONS REDUCTIONS GOALS. WE INTEND TO DESIGN A MEASUREMENT NETWORK AND DEVELOP AN ACCOMPANYING ATMOSPHERIC MODELING FRAMEWORK FOR DOWNSCALING THE CURRENT NASA CMS FLUX PRODUCTS TO THE REGIONAL AND LOCAL SCALES PERTINENT TO MONITORING, REPORTING, AND VERIFICATION (MRV). OUR PROPOSED RESEARCH WILL FOCUS ON THE BOSTON-DC MEGALOPOLIS CORRIDOR, WHERE ABOUT 17% OF THE U.S. POPULATION LIVES ON LESS THAN 2% OF THE NATION S LAND AREA, MAKING IT A KEY SOURCE OF US ANTHROPOGENIC CO2 EMISSIONS. SIMULTANEOUSLY, THESE URBAN AREAS ARE INTERSPERSED WITH VEGETATION THAT IMPOSES A STRONG BIOGENIC SIGNAL ON THE ATMOSPHERIC CO2 MIXING RATIOS. THE PROPOSED RESEARCH WILL PROCEED ALONG THREE MAIN LINES: 1) HIGH-RESOLUTION TRANSPORT MODELING (WRF-STILT) CUSTOMIZED AND VERIFIED FOR THE REGION, 2) HIGH-RESOLUTION CO2 FLUX MODEL INCORPORATING ANTHROPOGENIC EMISSIONS ESTIMATES AND THE CASA MODEL (INCLUDING ITS 0.5-DEG RESOLUTION VARIANT THAT PROVIDES THE FOUNDATIONAL BIOSPHERE MODEL FOR THE CURRENT CMS FLUX PRODUCT AND NESTED HIGHER RESOLUTION RUNS TO REPRESENT THE SCALE SENSITIVITY WITHIN HETEROGENEOUS URBAN AREAS), AND 3) INVERSE CO2 FLUX ESTIMATES CORRESPONDING TO IN-SITU AND REMOTE CO2 OBSERVATIONS IN AND AROUND BOSTON, NEW YORK CITY, AND WASHINGTON DC. AS PART OF THE PROPOSED WORK, WE WILL QUANTIFY ERRORS IN THE WRF-STILT SIMULATIONS OF THE PLANETARY BOUNDARY LAYER (PBL), RELYING FOR THIS PURPOSE ON REMOTELY SENSED PBL MEASUREMENTS BY THE SIGMA SPACE CORPORATION S MICRO PULSE LIDAR (MPL). THE PBL HEIGHT IS A KEY PARAMETER ENTERING INVERSE FLUX ESTIMATES, AS IT DETERMINES THE MIXING REGION AND VARIES INVERSELY TO THE TRACE GAS CONCENTRATIONS. A KEY RESULT OF THE PROPOSED RESEARCH WILL BE THE QUANTIFICATION OF OBSERVING REQUIREMENTS FOR FLUX UNCERTAINTY REDUCTION TO LEVELS NEEDED FOR MRV. OUR PROPOSAL ADDRESSES TWO STATED GOALS OF THE NNH13ZDA001N-CMS SOLICITATION: STUDIES USING COMMERCIAL OFF-THE-SHELF TECHNOLOGIES TO PRODUCE AND EVALUATE PROTOTYPE MRV SYSTEM APPROACHES AND STUDIES TO IMPROVE THE CHARACTERIZATION AND QUANTIFICATION OF ERRORS AND UNCERTAINTIES IN EXISTING AND/OR PROPOSED NASA CMS PRODUCTS, INCLUDING ERRORS AND UNCERTAINTIES IN THE ALGORITHMS, MODELS, AND ASSOCIATED METHODOLOGIES UTILIZED IN CREATING THEM. THE PROPOSED WORK WILL LEVERAGE AND EXTEND THE CURRENT CMS PROJECTS LED BY DRS. ARLYN ANDREWS AND STEVEN PAWSON, WITH WHICH THE LEAD PROPOSING TEAM AT ATMOSPHERIC AND ENVIRONMENTAL RESEARCH (AER) IS INTIMATELY INVOLVED, AND THE CMS PILOT SURFACE CARBON FLUXES MODELING ANALYSIS.
FY21 NAFMDVB ORDER FOR VAC FORM BG
BG - NAFMDVB PURCHASE BIOGENESIS BAGO S.A. CONTRACT #: 12639520D0055 QTY 2.5M DOSES C3 INDAIAL @.415/DOSE $1,037,500.
FY22 NAVVCB FMD VAC ORDER FROM BIOGENESIS BAGO S.A.
NEW TASK ORDER: ACCOUNTING FRAMEWORK FOR GHG EMISSIONS FROM BIOENERGY AND OTHER BIOGENIC SOURCES".
Source: USAspending.gov (Official Federal Award Data). Reflects prime contracts only. Last sync: 2026-03-30.
Compared to 180 peers in Biological Products, (No Diagnostic Substances) (SIC 2836)
Revenue
Net Margin
SEC EDGAR XBRL filings by fiscal year
Side-by-side financial showdown — revenue, margins, and growth.
America's #1 crypto exchange. Buy Bitcoin, Ethereum & 200+ coins.
Get Started Free →Affiliate link · sprytne.com may earn a commission
Methodology & compliance note
Data is aggregated from SEC EDGAR and Secretary of State public records. Any analytics such as "market share" are statistical estimates (proxy models) and are not official audits, valuations, or investment advice. Sprytne.com is an independent data aggregator and is not affiliated with any government agency.Learn more →